Medco/LabCorp Alliance May Yield AmpliChip Outcomes Data, Convince Payors to Cover Dx

The collaboration comes as the FDA is planning to update tamoxifen’s label with information about genetic testing, and may yield the kind of outcomes data that insurers said they need before agreeing to reimburse for Roche’s AmpliChip.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories